Impax Asset Management Group plc Has $13.24 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Impax Asset Management Group plc cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 67,782 shares of the company’s stock after selling 5,488 shares during the period. Impax Asset Management Group plc’s holdings in Zoetis were worth $13,243,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ZTS. Quarry LP boosted its stake in Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares during the last quarter. Fortitude Family Office LLC boosted its position in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. LRI Investments LLC acquired a new stake in shares of Zoetis during the first quarter worth $43,000. Central Valley Advisors LLC bought a new stake in Zoetis in the second quarter valued at about $49,000. Finally, Future Financial Wealth Managment LLC acquired a new position in Zoetis in the third quarter valued at about $59,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.1 %

Shares of Zoetis stock opened at $175.27 on Wednesday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The business’s 50 day simple moving average is $188.71 and its 200 day simple moving average is $179.23. The firm has a market cap of $79.41 billion, a PE ratio of 32.95, a P/E/G ratio of 2.68 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 52.59%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the firm earned $1.36 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.99%. Zoetis’s payout ratio is presently 32.52%.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.